{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:42:19Z","timestamp":1794375739628,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["525171148"],"award-info":[{"award-number":["525171148"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41591-026-04365-y","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:02:32Z","timestamp":1776704552000},"page":"2420-2429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9198-8338","authenticated-orcid":false,"given":"David M.","family":"Cordas dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bosch-Vilaseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"DeBraganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"McEntire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Arters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Kineavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Marto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-9572","authenticated-orcid":false,"given":"Hope","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7327-9140","authenticated-orcid":false,"given":"Emily","family":"Durlacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayda","family":"Bidikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Montes de Oca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Lengil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"De Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7430-1399","authenticated-orcid":false,"given":"Kevin","family":"Panaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-7587","authenticated-orcid":false,"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Tendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Wildgust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"4365_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4365_CR2","doi-asserted-by":"crossref","unstructured":"Jagannath, S. et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 2766\u22122771 (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.7507"},{"key":"4365_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"4365_CR4","doi-asserted-by":"crossref","unstructured":"Mateos, M.-V. et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update. Paper presented at 21st International Myeloma Society annual meeting, Rio de Janeiro, Brazil, 25\u201328 September, 2024; https:\/\/www.jnjmedicalconnect.com\/media\/attestation\/congresses\/oncology\/2024\/ims\/overall-survival-os-with-ciltacabtagene-autoleucel-ciltacel-versus-standard-of-care-soc-in-lenalidom.pdf","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"4365_CR5","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2021-146210","volume":"138","author":"D Dytfeld","year":"2021","unstructured":"Dytfeld, D. et al. Bortezomib, lenalidomide and dexamethasone (VRd) followed by ciltacabtagene autoleucel versus Vrd followed by lenalidomide and dexamethasone (Rd) maintenance in patients with newly diagnosed multiple myeloma not intended for transplant: a randomized, phase 3 study (CARTITUDE-5). Blood 138, 1835 (2021).","journal-title":"Blood"},{"key":"4365_CR6","doi-asserted-by":"crossref","unstructured":"Boccadoro, M. et al. DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EM agine\/CARTITUDE-6). Blood 140, 4630\u22124632 (2022).","DOI":"10.1182\/blood-2022-157021"},{"key":"4365_CR7","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 (2007).","journal-title":"Blood"},{"key":"4365_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"4365_CR9","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","volume":"10","author":"A Cowan","year":"2023","unstructured":"Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. Lancet Haematol. 10, e203\u2013e212 (2023).","journal-title":"Lancet Haematol."},{"key":"4365_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785\u2013789 (2008).","journal-title":"Blood"},{"key":"4365_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"4365_CR12","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi, P. et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 6, e454 (2016).","journal-title":"Blood Cancer J."},{"key":"4365_CR13","doi-asserted-by":"publisher","unstructured":"Chabrun, F. et al. Enhanced dynamic risk stratification of smoldering multiple myeloma. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-026-04304-x (2026).","DOI":"10.1038\/s41591-026-04304-x"},{"key":"4365_CR14","doi-asserted-by":"crossref","unstructured":"Alberge, J.-B. et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat. Genet. 57, 1493\u22121503 (2025).","DOI":"10.1038\/s41588-025-02196-0"},{"key":"4365_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1200\/JCO-25-00289","volume":"44","author":"A Aktas Samur","year":"2026","unstructured":"Aktas Samur, A. et al. Genomically smoldering multiple myeloma is not a distinct entity but a collection of monoclonal gammopathy of undetermined significance or multiple myeloma. J. Clin. Oncol. 44, 321\u2013334 (2026).","journal-title":"J. Clin. Oncol."},{"key":"4365_CR16","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1038\/s41588-025-02292-1","volume":"57","author":"F Maura","year":"2025","unstructured":"Maura, F. et al. Temporal genomic dynamics shape clinical trajectory in multiple myeloma. Nat. Genet. 57, 2203\u20132214 (2025).","journal-title":"Nat. Genet."},{"key":"4365_CR17","unstructured":"Sklavenitis-Pistofidis, R. et al. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 40, 1358\u22121373 (2022)."},{"key":"4365_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55308-5","volume":"16","author":"O Nadeem","year":"2025","unstructured":"Nadeem, O. et al. Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat. Commun. 16, 358 (2025).","journal-title":"Nat. Commun."},{"key":"4365_CR19","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N. Engl. J. Med. 392, 1777\u20131788 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4365_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M., Toenges, R., Bertamini, L., Alberge, J.-B. & Ghobrial, I. M. New horizons in our understanding of precursor multiple myeloma and early interception. Nat. Rev. Cancer 24, 867\u2013886 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"4365_CR21","doi-asserted-by":"crossref","unstructured":"Gagelmann, N. et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J. Clin. Oncol. 42, 1665\u22121675 (2024).","DOI":"10.1200\/JCO.23.02232"},{"key":"4365_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J. Hematol. Oncol. 16, 88 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"4365_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142, 865\u2013877 (2023).","journal-title":"Blood"},{"key":"4365_CR24","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/jama.2024.0792","volume":"331","author":"CH Gibbons","year":"2024","unstructured":"Gibbons, C. H. et al. Skin biopsy detection of phosphorylated \u03b1-synuclein in patients with synucleinopathies. JAMA 331, 1298\u20131306 (2024).","journal-title":"JAMA"},{"key":"4365_CR25","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","volume":"3","author":"AL Garfall","year":"2019","unstructured":"Garfall, A. L. et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 3, 2812\u20132815 (2019).","journal-title":"Blood Adv."},{"key":"4365_CR26","doi-asserted-by":"crossref","unstructured":"Rade, M. et al. A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. Cancer Cell 44, 586\u2212603 (2025).","DOI":"10.1016\/j.ccell.2025.10.014"},{"key":"4365_CR27","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos, D. M. et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat. Med. 30, 2667\u20132678 (2024).","journal-title":"Nat. Med."},{"key":"4365_CR28","doi-asserted-by":"publisher","first-page":"3247\u22123256","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"M-V Mateos","year":"2024","unstructured":"Mateos, M.-V. et al. Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance. J. Clin. Oncol. 42, 3247\u22123256 (2024).","journal-title":"J. Clin. Oncol."},{"key":"4365_CR29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani, S. Z. et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat. Med. 31, 1195\u20131202 (2025).","journal-title":"Nat. Med."},{"key":"4365_CR30","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2025.43.16_suppl.7501","volume":"43","author":"P Moreau","year":"2025","unstructured":"Moreau, P. et al. Subcutaneous daratumumab (Dara) + bortezomib\/lenalidomide\/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial. J. Clin. Oncol. 43, 7501 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4365_CR31","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.1200\/JCO.2025.43.16_suppl.7503","volume":"43","author":"CO Landgren","year":"2025","unstructured":"Landgren, C. O. et al. Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): the ADVANCE clinical trial. J. Clin. Oncol. 43, 7503 (2025).","journal-title":"J. Clin. Oncol."},{"key":"4365_CR32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4365_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"4365_CR34","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2016","unstructured":"Ghermezi, M. et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102, 785 (2016).","journal-title":"Haematologica"},{"key":"4365_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00505-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram, A. et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 11, 120 (2021).","journal-title":"Blood Cancer J."},{"key":"4365_CR36","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/bjh.16673","volume":"192","author":"S Jew","year":"2021","unstructured":"Jew, S. et al. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Br. J. Haematol. 192, 1064\u20131067 (2021).","journal-title":"Br. J. Haematol."},{"key":"4365_CR37","doi-asserted-by":"publisher","first-page":"1611171","DOI":"10.3389\/pore.2023.1611171","volume":"29","author":"\u00c1 Wiedemann","year":"2023","unstructured":"Wiedemann, \u00c1 et al. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma. Pathol. Oncol. Res. 29, 1611171 (2023).","journal-title":"Pathol. Oncol. Res."},{"key":"4365_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1182\/blood.2024026028","volume":"145","author":"D Ikeda","year":"2025","unstructured":"Ikeda, D. et al. Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma. Blood 145, 526\u2013532 (2025).","journal-title":"Blood"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04365-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:02:25Z","timestamp":1784210545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04365-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4365"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04365-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.N.: research funding from Bristol Myers Squibb and Johnson & Johnson; advisory boards for Johnson & Johnson, Bristol Myers Squibb, Sanofi, GPCR Therapeutics, Kite and AstraZeneca. D.M.C.d.S.: research funding from Regeneron. S.N.: no conflicts of interest to disclose. A.B.-V.: no conflicts of interest to disclose. E.O.: consulting for Exact Sciences, Natera, Grail and Sanofi; research funding from Regeneron. R.R.: no conflicts of interest to disclose. K.D. is an employee of Johnson & Johnson and has stock ownership. A.S.S. has consulted for Novartis and Janssen. Y.L. has participated on an advisory board for Opna Bio and has consulted for Sanofi. C.M.: no conflicts of interest to disclose. F.A.: no conflicts of interest to disclose. C.O.: no conflicts of interest to disclose. B.K.: no conflicts of interest to disclose. M.M.: no conflicts of interest to disclose. A.B.: no conflicts of interest to disclose. E.S.: no conflicts of interest to disclose. K.M.: no conflicts of interest to disclose. A.C.: no conflicts of interest to disclose. Q.B.: no conflicts of interest to disclose. H.W.: no conflicts of interest to disclose. E.D.: no conflicts of interest to disclose. E.G.: no conflicts of interest to disclose. F.C.: no conflicts of interest to disclose. N.B.: no conflicts of interest to disclose. R.M. is an employee of Johnson & Johnson and has stock ownership. T.L. is an employee of Johnson & Johnson and has stock ownership. D.D.W. is an employee of Johnson & Johnson and has stock ownership. C.G.: no conflicts of interest to disclose. K.P.: no conflicts of interest to disclose. E.L.S. has consulted for ArsenalBio, Blackstone Life Sciences, Chroma Medicine, Clade Therapeutics, Eureka Therapeutics, ImmuneBridge, Legend Biotech, Overland Pharmaceuticals, Predicta Biosciences and Sana Biotech. E.L.S. holds equity in Predicta Biosciences and receives research funding from Sanofi and Strand Therapeutics. E.L.S. is an inventor on licensed patents regarding CAR T cells and antibodies and received royalties from Bristol Myers Squibb, Sanofi and Vyriad. E.L.S. was on scientific advisory boards for Bristol Myers Squibb, Chimeric Therapeutics, Novartis and Sanofi. K.A. has consulted for Janssen, AstraZeneca, Pfizer and Roche\/Genentech. He is on the board of directors with stock options for Dynamic Cell Therapies, C4 Therapeutics, Starton Therapeutics and Window Therapeutics and has stock options in Predicta Biosciences. C.J. has received consulting fees from Kite\/Gilead, Novartis, Bristol Myers Squibb, Autolus, Miltenyi Biotec, Galapagos, Janssen, Umoja, Kyverna, Caribou, Lyell, ADC Therapeutics, AstraZeneca, AbbVie, GenmAb and Genentech and research funding from Kite\/Gilead. N.C.M. has consulted for Bristol Myers Squibb, Janssen, OncoPep, Amgen, Karyopharm, Legend, AbbVie, Takeda and GlaxoSmithKline. He is on the board of directors and has stock options for OncoPep. P.R.: consulting for Celgene\/Bristol Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, Regeneron and Sanofi; research grants from Oncopeptides and Karyopharm. D.M. is an employee of Johnson & Johnson and has stock ownership. J.S. is an employee of Johnson & Johnson and has stock ownership. C.T. was an employee of Johnson & Johnson and has stock ownership. M.W. is an employee of Johnson & Johnson and has stock ownership. L.T.: no conflicts of interest to disclose. M.V.M.: honoraria from AbbVie\/Genentech, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi and Takeda; consulting\/advisory roles for AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Regeneron, Roche\/Genentech and Takeda. J.R. has research funding from Kite\/Gilead and Novartis and serves on advisory boards for Astraveus, CGT Global, Smart Immune, Stratus Therapeutics, Tolerance Bio and Visterra. I.M.G. has consulted for AbbVie, Adaptive, Amgen, Aptitude Health, Arcellx, AstraZeneca, BioSkryb Genomics, Bristol Myers Squibb, Civala, Clinical Care Options, Clinical Education Alliance, ENGAGE, Feromics, Genentech, GlaxoSmithKline, Janssen, Kite Pharma, Menarini, ONK Therapeutics, Pfizer, Regeneron, Sanofi, Silicon Biosystems, Takeda, TG Therapeutics and Window Therapeutics. She has received honoraria from Amgen, Curio Science, Janssen, MD Education, MJH Life Sciences, Physicians\u2019 Education Resource, Regeneron, Standard Biotools, Takeda, Thermo Fisher Scientific\/Binding Site, Veeva and Vor Biopharma. She is a founder and executive board member of, and holds private equity in, Predicta Biosciences. Her spouse is the chief medical officer of, and holds private equity in, Disc Medicine.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}